Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Jason Yang, MD, PhD
Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC

October 31st 2024

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

FDA
FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

October 30th 2024

Maurie Markman, MD, of City of Hope
Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

October 30th 2024

Courtney DiNardo, MD, MSCE, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

October 28th 2024

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.
RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

October 28th 2024

More News